AKUMS DRUGS & PHARMACEUTICALS
Quarterly Results Analysis [Jun2025]
AKUMS DRUGS & PHARMACEUTICALS Quarterly Results
Consolidated | Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹1,024 Cr | ₹1,056 Cr | ₹1,010 Cr | ₹1,033 Cr | ₹1,019 Cr | ₹944 Cr | ₹1,083 Cr | ₹1,181 Cr |
Expenses | ₹895 Cr | ₹962 Cr | ₹889 Cr | ₹912 Cr | ₹891 Cr | ₹941 Cr | ₹989 Cr | ₹1,029 Cr |
Operating Income | ₹129 Cr | ₹94 Cr | ₹121 Cr | ₹121 Cr | ₹128 Cr | ₹3 Cr | ₹93 Cr | ₹152 Cr |
Other Income | ₹27 Cr | ₹18 Cr | ₹15 Cr | ₹13 Cr | ₹7 Cr | ₹10 Cr | ₹9 Cr | ₹7 Cr |
Interest | ₹23 Cr | ₹5 Cr | ₹5 Cr | ₹12 Cr | ₹13 Cr | ₹12 Cr | ₹12 Cr | ₹14 Cr |
Depreciation | ₹37 Cr | ₹40 Cr | ₹45 Cr | ₹35 Cr | ₹34 Cr | ₹34 Cr | ₹32 Cr | ₹30 Cr |
Profit Before Tax | ₹96 Cr | ₹75 Cr | ₹91 Cr | ₹92 Cr | ₹87 Cr | ₹-33 Cr | ₹59 Cr | ₹87 Cr |
Profit After Tax | ₹65 Cr | ₹150 Cr | ₹66 Cr | ₹67 Cr | ₹61 Cr | ₹-39 Cr | ₹195 Cr | ₹33 Cr |
EPS | ₹4.15 | ₹9.64 | ₹4.26 | ₹4.26 | ₹4.21 | ₹-2.89 | ₹13.54 | ₹2.22 |
Industry Peers & Returns | 1W | 1M | 1Y |
AKUMS DRUGS & PHARMACEUTICALS | -0.4% | -2.3% | -47.5% |
SUN PHARMACEUTICAL INDUSTRIES | 0.6% | 3.6% | -12.5% |
DIVIS LABORATORIES | 1% | 9.4% | 8% |
CIPLA | 0.9% | 1.2% | -0.2% |
TORRENT PHARMACEUTICALS | 1.7% | 1% | 1% |
DR REDDYS LABORATORIES | -0.5% | -4.2% | -6.3% |
MANKIND PHARMA | 1.5% | -3.5% | -10.6% |
ZYDUS LIFESCIENCES | -0.6% | -4.6% | -7% |
LUPIN | -1.6% | -4.5% | -13.3% |
AKUMS DRUGS & PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -2.99 % |
Y-o-Y | 0.48 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Jun2025 | ₹1,024 Cr | -2.99 | |
Mar2025 | ₹1,056 Cr | 4.47 | |
Dec2024 | ₹1,010 Cr | -2.19 | |
Sep2024 | ₹1,033 Cr | 1.37 | |
Jun2024 | ₹1,019 Cr | 7.93 | |
Mar2024 | ₹944 Cr | -12.80 | |
Dec2023 | ₹1,083 Cr | -8.33 | |
Sep2023 | ₹1,181 Cr | - |
AKUMS DRUGS & PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 37.33 % |
Y-o-Y | 0.74 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Jun2025 | ₹129 Cr | 37.33 | |
Mar2025 | ₹94 Cr | -22.62 | |
Dec2024 | ₹121 Cr | 0.15 | |
Sep2024 | ₹121 Cr | -5.34 | |
Jun2024 | ₹128 Cr | 4,182.94 | |
Mar2024 | ₹3 Cr | -96.80 | |
Dec2023 | ₹93 Cr | -38.46 | |
Sep2023 | ₹152 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 41.46 % |
Y-o-Y | 0.24 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Jun2025 | 12.59% | 41.46 | |
Mar2025 | 8.9% | -25.90 | |
Dec2024 | 12.01% | 2.39 | |
Sep2024 | 11.73% | -6.61 | |
Jun2024 | 12.56% | 3,825.00 | |
Mar2024 | 0.32% | -96.29 | |
Dec2023 | 8.63% | -32.84 | |
Sep2023 | 12.85% | - |
AKUMS DRUGS & PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -56.76 % |
Y-o-Y | 5.68 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Jun2025 | ₹65 Cr | -56.76 | |
Mar2025 | ₹150 Cr | 125.61 | |
Dec2024 | ₹66 Cr | -0.51 | |
Sep2024 | ₹67 Cr | 8.89 | |
Jun2024 | ₹61 Cr | Positive | |
Mar2024 | ₹-39 Cr | Negative | |
Dec2023 | ₹195 Cr | 496.54 | |
Sep2023 | ₹33 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -55.40 % |
Y-o-Y | 5.16 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Jun2025 | 6.32 % | -55.40 | |
Mar2025 | 14.17 % | 116.01 | |
Dec2024 | 6.56 % | 1.71 | |
Sep2024 | 6.45 % | 7.32 | |
Jun2024 | 6.01 % | Positive | |
Mar2024 | -4.18 % | Negative | |
Dec2023 | 18.01 % | 550.18 | |
Sep2023 | 2.77 % | - |
AKUMS DRUGS & PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -56.95 % |
Y-o-Y | -1.43 % |
Quarters | EPS | % Change | |
---|---|---|---|
Jun2025 | ₹4.15 | -56.95 | |
Mar2025 | ₹9.64 | 126.29 | |
Dec2024 | ₹4.26 | 0.00 | |
Sep2024 | ₹4.26 | 1.19 | |
Jun2024 | ₹4.21 | Positive | |
Mar2024 | ₹-2.89 | Negative | |
Dec2023 | ₹13.54 | 509.91 | |
Sep2023 | ₹2.22 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD